Takeda Pharmaceuticals America, Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, holds a $360,141,120 multiple-award Federal Supply Schedule contract (36F79718D0586) with the U.S. Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs (FSS-61-IB). As a prime contractor, Takeda leverages this IDV to efficiently supply critical oncology medications like ICLUSIG (ponatinib) and NINLARO (ixazomib) to VA medical facilities and Veterans Integrated Service Networks (VISNs) nationwide.
Takeda also holds a $123.5 million single-award Blanket Purchase Agreement (BPA) with the VA National Acquisition Center specifically for the supply of ICLUSIG. This streamlined procurement vehicle allows VA locations to easily place delivery orders for the specialty oncology drug. The BPA and associated task orders, valued between $13,000 to $340,000, do not utilize any set-aside designations, reflecting Takeda's status as a large, foreign-owned business. By fulfilling these federal contracts, Takeda Pharmaceuticals America, Inc. plays a key role in supporting the VA's mission to provide comprehensive healthcare services to veterans.
Generated 1/29/25, 9:09 AM